Adimmune Corp (4142) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.073x

Based on the latest financial reports, Adimmune Corp (4142) has a cash flow conversion efficiency ratio of -0.073x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-355.08 Million ≈ $-11.19 Million USD) by net assets (NT$4.85 Billion ≈ $152.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Adimmune Corp defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Adimmune Corp - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Adimmune Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Adimmune Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Adimmune Corp ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Martifer SGPS S.A LS:MAR	0.099x
Titan Mining Corp TO:TI	1.432x
Micware Co., Ltd. American Depositary Shares NASDAQ:MWC	N/A
Iljin Holdings KO:015860	0.059x
Pacific Current Group Ltd AU:PAC	0.026x
Anavex Life Sciences Corp NASDAQ:AVXL	-0.056x
Challenger Gold Ltd AU:CEL	-0.013x
All Iron Re I Socimi Sa MC:YAI1	0.053x

Annual Cash Flow Conversion Efficiency for Adimmune Corp (2007–2024)

The table below shows the annual cash flow conversion efficiency of Adimmune Corp from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see 4142 company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$5.56 Billion ≈ $175.22 Million	NT$668.48 Million ≈ $21.06 Million	0.120x	+177.82%
2023-12-31	NT$5.78 Billion ≈ $182.03 Million	NT$-892.35 Million ≈ $-28.11 Million	-0.154x	-246.22%
2022-12-31	NT$6.54 Billion ≈ $206.20 Million	NT$-291.96 Million ≈ $-9.20 Million	-0.045x	+40.28%
2021-12-31	NT$6.43 Billion ≈ $202.66 Million	NT$-480.52 Million ≈ $-15.14 Million	-0.075x	-121.33%
2020-12-31	NT$6.63 Billion ≈ $208.84 Million	NT$2.32 Billion ≈ $73.15 Million	0.350x	+630.21%
2019-12-31	NT$3.83 Billion ≈ $120.53 Million	NT$-252.72 Million ≈ $-7.96 Million	-0.066x	+79.62%
2018-12-31	NT$1.86 Billion ≈ $58.48 Million	NT$-601.74 Million ≈ $-18.96 Million	-0.324x	-11178.96%
2017-12-31	NT$2.35 Billion ≈ $74.02 Million	NT$6.87 Million ≈ $216.57K	0.003x	+101.17%
2016-12-31	NT$3.09 Billion ≈ $97.51 Million	NT$-773.53 Million ≈ $-24.37 Million	-0.250x	-146.38%
2015-12-31	NT$3.68 Billion ≈ $116.09 Million	NT$-373.82 Million ≈ $-11.78 Million	-0.101x	-8.59%
2014-12-31	NT$4.47 Billion ≈ $140.75 Million	NT$-417.35 Million ≈ $-13.15 Million	-0.093x	+46.82%
2013-12-31	NT$3.24 Billion ≈ $101.99 Million	NT$-568.64 Million ≈ $-17.92 Million	-0.176x	-60.56%
2012-12-31	NT$3.74 Billion ≈ $117.92 Million	NT$-409.48 Million ≈ $-12.90 Million	-0.109x	-34.00%
2011-12-31	NT$3.60 Billion ≈ $113.37 Million	NT$-293.77 Million ≈ $-9.26 Million	-0.082x	-164.23%
2010-12-31	NT$4.06 Billion ≈ $127.99 Million	NT$516.39 Million ≈ $16.27 Million	0.127x	-20.26%
2009-12-31	NT$3.77 Billion ≈ $118.67 Million	NT$600.42 Million ≈ $18.92 Million	0.159x	+472.28%
2008-12-31	NT$3.17 Billion ≈ $99.84 Million	NT$-135.69 Million ≈ $-4.28 Million	-0.043x	-363.61%
2007-12-31	NT$1.92 Billion ≈ $60.63 Million	NT$31.26 Million ≈ $984.86K	0.016x	--

About Adimmune Corp

TW:4142 Taiwan Biotechnology

Market Cap

$231.73 Million

NT$7.36 Billion TWD

Market Cap Rank

#16081 Global

#764 in Taiwan

Share Price

NT$17.45

Change (1 day)

-1.41%

52-Week Range

NT$16.00 - NT$21.55

All Time High

NT$77.19